Juhe Bio's CISCER® Cervical Cancer Screening Test: Advancing Early Detection and Global Elimination of Cervical Cancer

Cervical cancer is one of the common malignant tumors that seriously threaten women's health worldwide and ranks as the fourth leading cause of cancer-related deaths among women. In 2020, there were an estimated 604,000 new cases of cervical cancer and over 342,000 deaths globally. According to epidemiological statistics, China bears a significant burden of cervical cancer; in 2020, there were 109,000 new cases and 59,000 deaths in the country. Currently, both the incidence and mortality rates of cervical cancer in China continue to rise. Avoiding missed diagnoses during early cervical cancer screening, or providing timely and effective diagnosis, treatment, and management for detected precancerous lesions and early invasive cancers, are crucial measures to reduce the incidence or recurrence of cervical cancer, improve patient survival rates, and preserve female fertility.

VCBeat Selects New Products Review Issue 4, featuringProfessor Liu Yuli, The First Affiliated Hospital of Guangdong Pharmaceutical University; Professor Li Lei, Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Mr. Zhuang Xiangyu, Juhe BioProviding industry insights, clinical value explanations, and product introductions.

He Gong Kang CISCER^®The non-invasive early screening, precise diagnosis and treatment, accurate triage, and early diagnosis and intervention enabled by dual-gene methylation technology will further assist clinical decision-making. This approach suggests a new possibility for cervical cancer screening and diagnostic strategies based on fertility preservation, and will serve as a significant boost to China’s three-tier prevention and control system for cervical cancer, accelerating its elimination and improving women’s health and quality of life.

To provide everyone with a more comprehensive understanding, on Friday, March 31, 2023, from 19:30 to 20:30, Juhue Biotech’s Hekang CISCER^®The Dual-Gene Methylation Detection Kit will be launched at VCBeat Select's New Product Showcase.

For this event, we have invitedProfessor Liu Yuli, the First Affiliated Hospital of Guangdong Pharmaceutical University,Professor Li Lei, Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical SciencesOverview of Industry Background and Clinical Value，MeanwhileMr. Zhuang Xiangyu, Director of the Medical Affairs Department, Juhe BiotechnologyThe live broadcast will provide an overview of Juhao Biotechnology and present relevant commercial policies.

Prof. Liu Yuli

Researcher, The First Affiliated Hospital of Guangdong Pharmaceutical University

Serves as a member of the Reproductive Health Professional Committee of the China Association for the Promotion of Population Culture, a member of the Colposcopy and Cervical Lesions Professional Committee of the Chinese Medical Doctor Association’s Obstetrics and Gynecology Branch, a member of the Pharmacogenomics Professional Committee of the Chinese Pharmacological Society, and a member of the Integrative Medicine Professional Committee for Oral and Maxillofacial Tumors of the China Anti-Cancer Association. Has published more than 20 SCI-indexed articles and serves as an SCI journal reviewer and guest editor for special issues.

Professor Li Lei

Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical SciencesChief Physician, M.D., Master's Supervisor

Recipient of the Third Prize of the Chinese Medical Science and Technology Award, the First Prize of the Huaxia Medical Science and Technology Award, the Third-Class Merit of the Xinjiang Production and Construction Corps, and the First Prize (Scientific and Technological Achievement Award) of the National “Maternal and Child Health Science and Technology Award.”

As first author or corresponding author, published 54 articles in Chinese core journals and over 52 SCI-indexed articles (with a cumulative impact factor of 200); served as editor-in-chief for two books, namely Notes on Gynecologic Oncology from Peking Union Medical College Hospital – Volume I and Perspectives on Adenomyosis 2017, and participated in the writing, editing, and translation of more than ten other books. Serves as a Young Editorial Board Member of the Peking Union Medical Journal and as a Young Editorial Board Member of the Chinese Edition of Human Reproduction Update.

Zhuang Xiangyu, Director of Market Medical Affairs

Origin: Juhe Bio

Junior Technology Manager (National Professional in Technology Transfer); formerly affiliated with Hualian Biotechnology Co., Ltd. and Wuhan Guojian Bio-Pharmaceutical Co., Ltd.; currently serves as Marketing Director at Beijing Qiyuan Juhe Biotechnology Co., Ltd.

Beijing Origin Juhe Biotechnology Co., Ltd. is a technology-driven enterprise committed to advancing health through innovative science. As a pioneer in the early diagnosis of gynecological cancers, Juhe Biotechnology has developed diagnostic products for cervical, ovarian, and endometrial cancers, leveraging proprietary technologies and patented biomarkers to fill critical gaps in this field.

As women pay closer attention to their own health, the female health market holds significant promise. In addition to its product line for early screening and diagnosis of gynecological tumors, Juhuo Biotechnology will establish more product pipelines related to women's health in the future, aiming to become a leading technology-innovation enterprise in the female health market.

“Artery Select New Product Debut” is a live-streaming series under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower the milestone launch of every innovative medical product.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively contact the assistant)